The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 508.00
Bid: 506.00
Ask: 510.00
Change: -2.00 (-0.39%)
Spread: 4.00 (0.791%)
Open: 510.00
High: 510.00
Low: 506.00
Prev. Close: 508.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity and Total Voting Rights

26 Jan 2022 07:00

RNS Number : 6084Z
Marlowe PLC
26 January 2022
 

26 January 2022

 

 

Marlowe plc

("Marlowe", the "Company" or the "Group")

 

 

Issue of Equity and Total Voting Rights

 

 

Marlowe, the UK leader in business-critical services and software which assure regulatory compliance, announces that, following the achievement of profit targets in respect of the Group's 2020 acquisition of Elogbooks Facilities Management Limited and Elogbooks Facilities Services Limited (together with their subsidiaries, "Elogbooks"), final contingent consideration of £3.5m, including the issue of 93,016 new ordinary shares of 50 pence each in the Group (the "New Ordinary Shares") at an effective issue price of 1025 pence per ordinary share, will be payable by the Group in respect of the Acquisition.

 

Application has been made for 93,016 New Ordinary Shares to be admitted to trading on AIM ("Admission"). The New Ordinary Shares will rank pari passu with the Group's existing ordinary shares, and it is expected that Admission will occur at 8.00am on 27 January 2022.

 

Following Admission, the Company's issued ordinary share capital will comprise 95,833,853 ordinary shares, none of which are held in treasury. Therefore, the total number of ordinary shares with voting rights in Marlowe following admission will be 95,833,853 ordinary shares.

 

The above figure of 95,833,853 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information:

 

Marlowe plc

 

www.marloweplc.com

Alex Dacre, Chief Executive

Tel: +44 (0) 203 841 6194

Adam Councell, Chief Financial Officer

IR@marloweplc.com

Julian Wais, Head of Investor Relations

Cenkos Securities plc

Nominated Adviser and Joint Broker

Tel: +44 (0)20 7397 8900

Nicholas Wells

Ben Jeynes

George Lawson

Joh. Berenberg, Gossler & Co. KG, London Branch

Joint Broker

Tel: +44 (0)20 3207 7800

Mark Whitmore

Ben Wright

Dan Gee-Summons

 

FTI Consulting

Tel: +44 (0)20 3727 1340

Nick Hasell

Alex Le May

 

 

About Marlowe plc

 

Marlowe is a UK leader in business-critical services and software which assure safety and regulatory compliance. The company was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated safety and compliance services. It is focused on compliance software, eLearning, health & safety, employment law & HR compliance, fire safety & security, water & air hygiene and occupational health services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides software to over 1 million users and services to over 25% of Britain's commercial premises. The Group provides customers with a single outsourced, nationwide, provider of a range of regulated compliance and safety solutions. Our customers can be found in office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBAMFTMTJTBBT
Date   Source Headline
30th Apr 20247:00 amRNSTotal Voting Rights
8th Apr 20242:54 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20244:45 pmRNSBlock listing Interim Review
18th Mar 20247:00 amRNSBoard Changes; Update re: Returns of Capital
26th Feb 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
22nd Feb 20247:00 amRNSDisposal and Directorate Change
15th Jan 202410:23 amRNSChange of Nominated Adviser and Joint Broker
30th Nov 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSInterim results for the six months to 30 Sept 2023
23rd Nov 20237:00 amRNSNotice of Interim Results
31st Oct 20234:30 pmRNSTotal Voting Rights
27th Sep 20235:18 pmRNSHolding(s) in Company
26th Sep 20233:23 pmRNSBlock Admission
13th Sep 20236:15 pmRNSResult of AGM
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.